Why Pfizer Inc. (PFE) stock moved
Pfizer Inc. (PFE) shares fell 1.2% to $24.75 as of July 20, 2026, a modest decline from the prior close of $25.05. BestStocks flagged the session as a major change for PFE. Below, we break down what changed for PFE, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
PFE fell 1.2% to $24.75
PFE fell 1.2% in its latest session, moving from $25.05 to $24.75.
What it means for Pfizer Inc. investors
For Pfizer Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive price momentum; Positive price momentum. Weighing against that: Negative session, down 1.2%; Negative price action. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in PFE's fundamentals. Wall Street's consensus price target sits at $26.89, implying +8.6% upside from $24.75. Over the past 90 days analysts logged 1 upgrade and 1 downgrade. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 15 days out, the next report is the most likely near-term test of the move.
PFE price reaction
PFE last traded at $24.75, down $0.30 (-1.20%) from the previous close of $25.05. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Its healthcare peer group moved a median -1.7% over the same stretch, leaving PFE essentially in line with peers. Over the past month the stock has ranged between $23.67 and $25.14, and it currently sits about 73% of the way up that band.
Bullish and bearish analyst opinions on Pfizer Inc. (PFE)
The consensus analyst price target on Pfizer Inc. (PFE) is $26.89, 8.6% above the recent $24.75. Over the past 90 days analysts logged 1 upgrade, 6 maintains, and 1 downgrade. Here is how the bullish and bearish cases on PFE line up.
The bullish case
- Wall Street's consensus price target of $26.89 implies +8.6% upside from $24.75.
- The Street's most bullish target is $30.00 (+21.2%).
- 1 analyst upgrade in the past 90 days, most recently RBC Capital to Sector Perform (2026-06-10).
- Positive price momentum.
The bearish case
- 1 analyst downgrade in the past 90 days, most recently HSBC to Hold (2026-07-06).
- Negative session, down 1.2%.
- Negative price action.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for PFE
Frequently asked questions about PFE
Why did Pfizer Inc. (PFE) stock move?
PFE fell 1.2% to $24.75. No single company-specific catalyst was confirmed during the move window, and it looks like a sector-wide move.
How much did PFE stock fall?
PFE lost 1.20% ($0.30) versus the prior close of $25.05, last trading at $24.75 on 0.9× average volume.
When is Pfizer Inc.'s next earnings date?
PFE's next earnings report is estimated for 2026-08-04 — about 15 days away.
What is the analyst price target for PFE?
The consensus analyst price target for PFE is $26.89, about 8.6% above the current $24.75. Over the past 90 days, analysts recorded 1 upgrade, 6 maintains, and 1 downgrade.
Is the PFE move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median -1.7% against PFE's -1.2%. PFE ranks top 4 of 7 peers.
How BestStocks tracks PFE
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared PFE-specific materiality thresholds, triggering an evidence check. It draws on 5 tracked change events for PFE, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.